Although EGFR-TKIs are promising therapeutics for EGFR mutation-positive patients, it should be carefully administered to patients with accompanying COPD, pneumonitis, and pneumonia, and enrichment of inflammatory cytokines. The gene discussed is EGFR; the disease is chronic obstructive pulmonary disease.